Stock Earnings

Question 1

What are Cartesian Therapeutics Inc's key financial statements?

Accepted Answer

According to the latest financial statement (Form-10K), Cartesian Therapeutics Inc has a total asset of $435, Net loss of $-77

Question 2

What are the key financial ratios for RNAC?

Accepted Answer

Cartesian Therapeutics Inc's Current ratio is 0.98, has a Net margin is -202.63, sales per share of $2.19.

Question 3

How is Cartesian Therapeutics Inc's revenue broken down by segment or geography?

Accepted Answer

Cartesian Therapeutics Inc largest revenue segment is Nanoparticle Immunomodulatory Drugs, at a revenue of 26,004,000 in the most earnings release.For geography, United States is the primary market for Cartesian Therapeutics Inc, at a revenue of 26,004,000.

Question 4

Is Cartesian Therapeutics Inc profitable?

Accepted Answer

no, according to the latest financial statements, Cartesian Therapeutics Inc has a net loss of $-77

Question 5

Does Cartesian Therapeutics Inc have any liabilities?

Accepted Answer

yes, Cartesian Therapeutics Inc has liability of 441

Question 6

How many outstanding shares for Cartesian Therapeutics Inc?

Accepted Answer

Cartesian Therapeutics Inc has a total outstanding shares of 25.76

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	1	38	26	110	85	16
Revenue Growth (YoY)	-98%	46%	-76%	28.99%	430.99%	167%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	30	30	40	23	20	18
Research & Development	54	45	71	72	68	54
Operating Expenses	93	75	111	96	89	73
Other Non Operating Income (Expenses)	36	-33	-4	21	-2	-10
Pretax Income	-47	-77	-238	34	-9	-68
Income Tax Expense	--	0	-19	0	15	--
Net Income	-50	-77	-219	35	-25	-68
Net Income Growth	-80%	-65%	-726%	-240%	-63%	24%
Shares Outstanding (Diluted)	26	17.27	5.17	4.86	3.81	3.37
Shares Change (YoY)	21%	234%	6%	28%	13%	122%
EPS (Diluted)	-1.94	-4.48	-42.5	7.28	-6.74	-20.42
EPS Growth	-83%	-89%	-684%	-208%	-67%	-44%
Free Cash Flow	-68	-32	-51	-32	-61	34
Free Cash Flow Per Share	-2.61	-1.85	-9.86	-6.58	-16	10.08
Gross Margin	--	--	--	--	--	--
Operating Margin	-9,100%	-94.73%	-326.92%	12.72%	-4.7%	-350%
Profit Margin	-5,000%	-202.63%	-842.3%	31.81%	-29.41%	-425%
Free Cash Flow Margin	-6,800%	-84.21%	-196.15%	-29.09%	-71.76%	212.5%
EBITDA	-89	-35	-85	15	-3	-56
EBITDA Margin	-8,900%	-92.1%	-326.92%	13.63%	-3.52%	-350%
D&A For EBITDA	2	1	0	1	1	0
EBIT	-91	-36	-85	14	-4	-56
EBIT Margin	-9,100%	-94.73%	-326.92%	12.72%	-4.7%	-350%
Effective Tax Rate	--	0%	7.98%	0%	-166.66%	--

Cartesian Therapeutics Inc (RNAC) Price

RNAC Stock Price Chart

RNAC Income

Follow-Up Questions